A Retrospective Study of Fulvestrant Monotherapy in HR-positive, HER2-negative Advanced Breast Cancer – a Real-life Experience in a UK Centre

Purpose: The study aim was to assess the demographics and clinical outcomes of patients with hormone receptor-positive, HER2-negative advanced breast cancer who received single-agent fulvestrant, a selective oestrogen receptor degrader (SERD), in East and North Hertfordshire NHS Trust.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research